| |
THBS1†
|
Cyr61†
|
CTGF†
|
|---|
| |
n
|
-
|
+
|
P
|
n
|
-
|
+
|
P
|
n
|
-
|
+
|
P
|
|---|
|
Age(years)
| | | | | | | | | | | | |
|
≤ 57
|
43
|
6
|
37
|
0.494
|
43
|
21
|
22
|
0.987
|
43
|
25
|
18
|
0.184
|
|
>57
|
37
|
3
|
34
| |
37
|
18
|
19
| |
37
|
16
|
21
| |
|
Gender
| | | | | | | | | | | | |
|
Male
|
58
|
6
|
52
|
0.700
|
58
|
29
|
29
|
0.805
|
58
|
33
|
25
|
0.101
|
|
Female
|
22
|
3
|
19
| |
22
|
10
|
12
| |
22
|
8
|
14
| |
|
Regional lymph node
| | | | | | | | | | | | |
|
N0
|
48
|
2
|
46
|
0.026*
|
48
|
23
|
25
|
0.855
|
48
|
27
|
21
|
0.273
|
|
N1
|
32
|
7
|
25
| |
32
|
16
|
16
| |
32
|
14
|
18
| |
|
Primary tumor
| | | | | | | | | | | | |
|
T1
|
4
|
1
|
3
| |
4
|
2
|
2
| |
4
|
3
|
1
| |
|
T2
|
6
|
0
|
6
| |
6
|
3
|
3
| |
6
|
2
|
4
| |
|
T3
|
64
|
7
|
57
|
0.479
|
64
|
30
|
34
|
0.868
|
64
|
34
|
30
|
0.501
|
|
T4
|
6
|
1
|
5
| |
6
|
4
|
2
| |
6
|
2
|
4
| |
|
Histologic grade
| | | | | | | | | | | | |
|
Well differentiated
|
24
|
1
|
23
| |
24
|
11
|
13
| |
24
|
11
|
13
| |
|
Moderately differentiated
|
48
|
6
|
42
|
0.179
|
48
|
22
|
26
|
0.355
|
48
|
26
|
22
|
0.844
|
|
Poorly differentiated
|
8
|
2
|
6
| |
8
|
6
|
2
| |
8
|
4
|
4
| |
|
TNM Stage
| | | | | | | | | | | | |
|
I/IIa
|
45
|
1
|
44
| |
45
|
21
|
24
| |
45
|
26
|
19
| |
|
IIb/III
|
35
|
8
|
27
|
0.009*
|
35
|
18
|
17
|
0.673
|
35
|
15
|
20
|
0.185
|
|
ESCC
|
80
|
8
|
72
| |
80
|
39
|
41
| |
80
|
41
|
39
| |
|
Normal mucosa
|
38
|
31
|
7
|
0.000*
|
38
|
34
|
4
|
0.000*
|
38
|
30
|
8
|
0.004*
|
- TNM: tumor node metastasis; †: (-) = nonoverexpressor; (+) = overexpressor.
- *Significant at P < 0.05 level.
